Current treatment in COVID-19 disease: a rapid review

Drugs in Context

article

Miguel Rodriguez-Guerra¹  Preeti Jadhav²  Timothy J Vittorio² 

[1] Department of Internal Medicine, BronxCare Hospital Center;Division of Cardiology, BronxCare Hospital Center

关键词: convalescent plasma;    COVID-19;    eculizumab;    immunoglobulins;    neutralizing IgG1 monoclonal antibodies;    remdesivir;    SARS-CoV-2;    steroids;    tocilizumab;   

DOI  :  10.7573/dic.2020-10-3

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

The world has faced the most challenging pandemic of the modern era, that of severe acute respiratory syndrome coronavirus 2 infection, causing coronavirus disease and affecting over 35 million people globally. The wide range of clinical manifestations associated with this viral disease is thought to be related to the overexpression of inflammatory markers. Due to a dysregulated host response, the most severe form involves multi-organ failure and thromboembolic complications. Immunomodulatory therapies may help prevent its progression and anticoagulation has been shown to reduce the risk of thrombotic complications. As this is a new entity for the medical world, there are no known therapeutic options nor has the prevention of complications been established. Anti-inflammatory agents, antimicrobial therapy, and vitamin supplements are short of clear benefits, but there is limited data to review. Other agents, such as convalescent plasma, eculizumab, immunoglobulins, neutralizing IgG1 monoclonal antibodies, remdesivir, steroids, and tocilizumab, have shown a possible impact on inpatient length of stay and mortality rate. This review aims to assess the efficacy and safety of these available therapies in light of current evidence. We compare these treatment options based on their impact on symptom management, inpatient length of stay, and overall morbidity and mortality.

【 授权许可】

CC BY-NC-ND